Biopharmaceuticals
Oncology
FDA
News Release - December 31, 2024
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
Source: Kazia Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.